Loading...
Loading...
IOVA| Name | Value |
|---|---|
| Revenues | 58.6M |
| Cost of Revenue | 39.8M |
| Gross Profit | 18.7M |
| Operating Expense | 107.8M |
| Operating I/L | -89.1M |
| Other Income/Expense | 4.0M |
| Interest Income | 4.0M |
| Pretax | -85.1M |
| Income Tax Expense | -1.5M |
| Net Income/Loss | -83.5M |
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in cancer immunotherapy products. It focuses on developing and commercializing treatments that utilize a patient's immune system to eradicate cancer cells. The company's lead product candidate, lifileucel, is being studied in six ongoing phase 2 clinical trials for metastatic melanoma, recurrent cervical cancer, and head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with leading cancer centers and pharmaceutical companies, positioning itself as a key player in the cancer immunotherapy market.
